NCT02716428View on ClinicalTrials.gov

A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

September 30, 2017

Study Completion Date

September 30, 2017

Conditions

Hepatitis C Viral InfectionChronic Hepatitis CHepatitis C (HCV)Hepatitis C Genotype 1

Interventions

DRUG

Faldaprevir

DRUG

TD-6450

DRUG

Ribavirin

Trial Locations (6)

34209

Bach and Godofsky Infectious Diseases, Bradenton

38138

Gastro One, Germantown

92118

Southern California Research Center, Coronado

Unknown

Auckland Clinical Studies, Auckland

Dunedin Hospital, Dunedin

Waikato Hospital, Waikato

All Listed Sponsors

lead

Trek Therapeutics, PBC

INDUSTRY

NCT02716428 - A Study of Faldaprevir, TD-6450 and Other Antivirals in Participants With Genotype 1b Hepatitis C Virus Infection | Biotech Hunter | Biotech Hunter